Delmitide acetate

Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL)-12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis[1][2].

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> IFNAR

Delmitide acetate (oral; 2.5, 5, 10 mg/kg; daily) significantly reduced CPT-11induced diarrhea, mucosal inflammation, and mortality in mice by suppressing the overproduction of proinflammatory cytokines TNF-a, IFN-y, and IL-12 in vivo[2]. Delmitide acetate (oral; 2.5, 5, 10 mg/kg; daily) generates an enhanced tumor response and prolongation of time to relapse without concomitant Gl toxicity in mice[2].

[1]. Arthur Kaser, et al. Novel therapeutic targets in the treatment of IBD. Kaser, Arthur; Tilg, Herbert (2008). Expert Opinion on Therapeutic Targets, 12(5), 553–563.

[2]. Jingsong Zhao, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004 Apr 15;10(8):2851-9.